http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112143764-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P41-002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-19 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P17-10 |
| filingDate | 2020-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112143764-B |
| titleOfInvention | Method for preparing intermediate compound of brivaracetam by using biological enzyme catalysis |
| abstract | The invention relates to a method for preparing a brivaracetam intermediate compound under the catalysis of biological enzymes, wherein the brivaracetam intermediate compound has a structure shown in a formula (I), and the method takes a compound (II) as a substrate and N-ethylmaleimide reductase as a catalyst to prepare the compound (I) through asymmetric hydrogenation reaction; the amino acid sequence of the N-ethylmaleimide reductase is shown as SEQ ID NO.2, SEQ ID NO.4 or SEQ ID NO. 6. The invention has the following beneficial effects: (1) the compound (II) is selected as a chiral intermediate for synthesizing the Buvaracetas, the preparation is easy, the catalytic hydrogenation reaction rate is high, the conversion rate is high, and the next reaction is easy to perform; (2) the invention adopts N-ethylmaleimide reductase shinEMR, camNEMR and cfrNEMR, can realize the high-efficiency and high-enantiomer selectivity production of the compound I by a one-step method, and has the advantages of high substrate conversion rate>99% enantiomeric selection>98％。 |
| priorityDate | 2020-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 747.